Skip to main content
SpringerLink
Log in

Clinical Observations of Sertindole in 53 Hospitalised Patients with Psychotic Disorders

  • Short Communication
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Bickmann E, Groβe K, Laux G. Klinische Beobachtungen an schizophrenen Patienten unter Behandlung mit Sertindol. Psychopharmakotherapie 2001; 8: 28–34

    Google Scholar 

  2. Hyttel J, Arnt J, Costall B, et al. Pharmacological profile of the atypical neuroleptic sertindole. Clin Neuropharmacol 1992; 15 Suppl. 1: 267A–8

    Article  PubMed  Google Scholar 

  3. Hyttel J, Nielsen JB, Nowak G. The acute effect of sertindole on brain 5-HT2, D2 and alpha1 receptors (ex vivo radio receptor binding studies). J Neural Transm Gen Sect 1992; 89: 61–9

    Article  PubMed  CAS  Google Scholar 

  4. Sanchez C, Arnt J, Costall B, et al. Sertindole: a limbic-selective neuroleptic with potent anxiolytic effects. Drug Dev Res 1995; 34: 19–29

    Article  CAS  Google Scholar 

  5. Domeney AM, Arnt J, Costall B, et al. Effect of sertindole on raised mesolimbic dopaminergic activity in the rat. Drug Dev Res 1994; 31: 175–85

    Article  CAS  Google Scholar 

  6. Daniel DG, Wozniak P, Mack RJ, etal. Long term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacol Bull 1998; 34: 61–9

    PubMed  CAS  Google Scholar 

  7. Lee AM, Knoll JL, Suppes T. The atypical antipsychotic sertindole: a case series. J Clin Psychiatry 1997; 58: 410–6

    Article  PubMed  CAS  Google Scholar 

  8. Brown LA, Levin GM. Sertindole, a new atypical antipsychotic for the treatment of schizophrenia. Pharmacotherapy 1998; 18: 69–83

    PubMed  CAS  Google Scholar 

  9. Fritze J, Bandelow B. QT-Verlängerung und das neue, atypische Neuroleptikum Sertindol. Psychopharmakotherapie 1998; 5: 115–20

    Google Scholar 

  10. Lundbeck A/S, Sertindole: Product Monograph. Copenhagen: H. Lundbeck A/S, 1997: 6-81

  11. Lundbeck A/S. Sertindole: summary of product characteristics. Copenhagen: H. Lundbeck A/S, 1996: 3-13

  12. Tamminga CA, Mack RJ, Granneman GR, et al. Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Int Clin Psychopharmacol 1997; 12 Suppl. 1: 29–35

    Article  Google Scholar 

  13. Van Kammen DP, McEvoy JP, Targum SD, et al. A randomised, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996; 124: 168–75

    Article  Google Scholar 

  14. Zimbroff DL, Kane JM, Tamminga CA, et al. A controlled, dose-response study of sertindole and haloperidol in schizophrenia. Am J Psychiatry 1997; 154: 782–91

    PubMed  CAS  Google Scholar 

  15. Editorial. Zum Risikoprofil von Sertindol (Serdolect). Arzneitelegramm 1997; 12: 128

  16. American Psychiatric Association (APA), DSM-III-R. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington: APA, 1987

    Google Scholar 

  17. CIPS. Internationale Skalen für Psychiatrie. Weinheim: Beliz, 1986

    Google Scholar 

  18. International statistical classification of diseases and related health problems, tenth revision. Geneva: World Health Organization, 1992

  19. Hale A, Azorin JM, Kasper S, et al. Sertindole improves both the positive and negative symptoms of schizophrenia: results of a phase III trial. Int J Psychiat Clin Pract 2000; 4(1): 55–62

    Article  CAS  Google Scholar 

  20. Azorin JM, Toumi M, Sloth-Nielsen M. Sertindole is well tolerated and demonstrates efficacy advantages over risperidone in the treatment of moderate to severe schizophrenia [abstract]. Eur Neuropsychopharmacol 2002; 12 Suppl. 3: S300

    Article  Google Scholar 

Download references

Acknowledgements

There was no funding for this study, and the authors have no conflicts of interest directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Department of Psychiatry I, Weissenau, Ulm University, Ulm, Germany

    Tilman Steinert, Barbara Hauger, Jürgen Eckardt & Peter Schmid

Authors
  1. Tilman Steinert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara Hauger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jürgen Eckardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Schmid
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tilman Steinert.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steinert, T., Hauger, B., Eckardt, J. et al. Clinical Observations of Sertindole in 53 Hospitalised Patients with Psychotic Disorders. Clin. Drug Investig. 25, 79–83 (2005). https://doi.org/10.2165/00044011-200525010-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200525010-00007

Keywords

Search

Navigation